Recent Updates
Recently added Catalysts

ADX10059

Phase 2

Gastroesophageal Reflux | Small molecule | Gastrointestinal |Addex Therapeutics Ltd|Last Updated: Jul 16, 2012

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials2
Total Enrollment418
FDA Designations
No designations recorded
Clinical trial landscape

ADX10059 · 2 trials · 1 indication

Phase 2 2
NCT00810485ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)Gastroesophageal Reflux
COMPLETED298 Analytics
NCT00820079ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)Gastroesophageal Reflux
COMPLETED120 Analytics
PHASE2COMPLETED
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
Gastroesophageal Reflux
NCT00810485298
Unlock trial analytics
PHASE2COMPLETED
ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)
Gastroesophageal Reflux
NCT00820079120
Unlock trial analytics
Study Endpoints
Primary Endpoints
Number of GERD symptom free days in week 4 of study medication treatment
4 weeks
Number of GERD symptom free days in week 2 of study medication treatment
2 weeks
Secondary Endpoints
GERD symptoms
4 weeks
Sleep disturbance
4 weeks
Use of antacid medications
4 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ADX10059 50 mgEXPERIMENTALtwice-daily
ADX10059 100 mgEXPERIMENTALtwice-daily
ADX10059 150 mgEXPERIMENTALtwice-daily
ADX10059 Matching PlaceboPLACEBO_COMPARATORtwice-daily
ADX10059 120 mgEXPERIMENTALTwice-daily
Interventions
NameTypeDescription
ADX10059DRUGoral administration
ADX10059 Matching PlaceboDRUGoral administration
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites40

Inclusion Criteria: * diagnosis of typical GERD * partial responder to a stable standard clinical symptoms control dose of PPI therapy * body mass index ≤ 32 kg/m2 Exclusion Criteria: * exclusively atypical symptoms of GERD * symptoms that have been shown not to be associated with GERD * erosive ...

Countries:United StatesFranceGermanyNetherlandsSwitzerlandAustriaBelgium
Unlock Eligibility Criteria